IPSC - NASDAQ
Century Therapeutics, Inc.
$2.07
-5.5%Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
At a Glance
Live SnapshotCentury Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Century Therapeutics, Inc. Income Statement
IPSC • NASDAQ
| Century Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
109.2M | 6.6M | 2.2M | 5.2M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(13.1M) | (0.0) | (0.0) | (0.0) | (4.6M) | (1.8M) | (249K) | |
96.1M | 6.6M | 2.2M | 5.2M | -4.6M | -1.8M | -249K | |
OPERATING INCOME | |||||||
(111.1M) | (144.7M) | (148.8M) | (139M) | (90.3M) | (47.4M) | (20M) | |
(24M) | (33.2M) | (34.7M) | (31.9M) | (14.7M) | (7.7M) | (5.8M) | |
(95.7M) | (107.2M) | (92.7M) | (97.2M) | (75.6M) | (39.7M) | (14.3M) | |
-15M | -138.1M | -146.5M | -133.8M | -94.9M | -49.2M | -246M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (540K) | (0.0) | (1.3M) | (381K) | (0.0) | |
7.3M | 13M | 12.1M | 3M | -377K | 323K | 0.0 | |
-8.6M | (4.3M) | (21.4M) | (10M) | (0.0) | (0.0) | (1.2M) | |
5.4M | 13.4M | 11.8M | 3M | -898K | -4.4M | 1.2M | |
-9.6M | -124.8M | -134.8M | -130.8M | -95.8M | -53.6M | -244.8M | |
NET INCOME | |||||||
-68K | (1.8M) | (1.9M) | (91K) | (43K) | (0.0) | (1.2M) | |
-9.6M | -126.6M | -136.7M | -130.9M | -95.8M | -53.6M | -246M |
SEC Filings
IPSC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | February 05, 2026 | February 05, 2026 | ||
8-K 8-K 2026 N/A | January 23, 2026 | January 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 07, 2026 | 2026 |
Related Guides
Continue your IPSC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.